BiotechTube

Datopotamab deruxtecan + Durvalumab + Carboplatin + Pembrolizumab + Cisplatin + Pemetrexed + Paclitaxel

Phase 3Active
1 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NSCLC

Conditions

NSCLC

Trial Timeline

Dec 29, 2022 → Nov 1, 2027

NCT ID
NCT05687266

About Datopotamab deruxtecan + Durvalumab + Carboplatin + Pembrolizumab + Cisplatin + Pemetrexed + Paclitaxel

Datopotamab deruxtecan + Durvalumab + Carboplatin + Pembrolizumab + Cisplatin + Pemetrexed + Paclitaxel is a phase 3 stage product being developed by AstraZeneca for NSCLC. The current trial status is active. This product is registered under clinical trial identifier NCT05687266. Target conditions include NSCLC.

What happened to similar drugs?

7 of 20 similar drugs in NSCLC were approved

Approved (7) Terminated (3) Active (11)
✅DurvalumabAstraZenecaApproved
✅OsimertinibAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Gefitinib + PlaceboAstraZenecaApproved
✅CrizotinibPfizerApproved
✅crizotinibPfizerApproved
✅NivolumabBristol Myers SquibbApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05687266Phase 3Active

Competing Products

20 competing products in NSCLC

See all competitors
ProductCompanyStageHype Score
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/CarboplatinWuXi BiologicsPhase 3
37
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
BBP-398 + osimertinibLianBioPhase 1
11
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)BioAtlaPhase 1/2
26
YH42946YuhanPhase 1/2
39
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + OsimertinibDaiichi SankyoPhase 1
33
U3-1287 + Erlotinib + PlaceboDaiichi SankyoPhase 1/2
32
DS-1205c + OsimertinibDaiichi SankyoPhase 1
21
Datopotamab deruxtecan (Dato-DXd) + DocetaxelDaiichi SankyoPhase 3
47
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789Daiichi SankyoPhase 1
33
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + CisplatinDaiichi SankyoPhase 1
33
HER3-DXd (FL-DP) + HER3-DXd (CTM-1 Lyo-DP) + HER3-DXd (CTM-3 Lyo-DP)Daiichi SankyoPhase 1
33
CS-7017 + erlotinibDaiichi SankyoPhase 2
35
gilteritinibAstellas PharmaPhase 1
36
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
35
naquotinib + midazolamAstellas PharmaPhase 1
29
OSI-906 + Erlotinib + PlaceboAstellas PharmaPhase 2
35
ExisulindAstellas PharmaPhase 1/2
32
naquotinibAstellas PharmaPhase 1
21
ASP8273Astellas PharmaPhase 2
27